Get the Stockscreener App
4.67
1.97%
0.09
Arbutus Biopharma Corp stock is traded at $4.67, with a volume of 1.44M.
It is up +1.97% in the last 24 hours and up +1.30% over the past month.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
See More
Previous Close:
$4.58
Open:
$4.6
24h Volume:
1.44M
Relative Volume:
0.74
Market Cap:
$923.95M
Revenue:
$191.45M
Net Income/Loss:
$160.72M
P/E Ratio:
5.6778
EPS:
0.8225
Net Cash Flow:
$-34.44M
1W Performance:
+0.86%
1M Performance:
+1.30%
6M Performance:
+17.34%
1Y Performance:
+38.58%
1-Day Range:
$4.55
$4.71
1-Week Range:
$4.42
$4.72
52-Week Range:
$3.31
$5.38
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Name
Arbutus Biopharma Corp
Sector
Industry
Phone
604-419-3200
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.67 | 908.12M | 191.45M | 160.72M | -34.44M | 0.8225 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-22 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Initiated | Jefferies | Hold |
| Dec-17-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Resumed | JMP Securities | Mkt Outperform |
| Jul-24-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-19-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-06-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-20-20 | Initiated | Robert W. Baird | Outperform |
| Feb-05-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Oct-07-19 | Reiterated | B. Riley FBR | Buy |
| Oct-04-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
| Oct-12-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-06-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Mar-19-18 | Resumed | Chardan Capital Markets | Buy |
| Mar-19-18 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-04-17 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-01-17 | Reiterated | Wedbush | Outperform |
| Dec-13-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-30-16 | Upgrade | Chardan Capital Markets | Neutral → Buy |
View All
Arbutus Biopharma Corp Stock (ABUS) Latest News
Arbutus Biopharma (NASDAQ:ABUS) Cut to Hold at Wall Street Zen - MarketBeat
Arbutus Biopharma (ABUS) Stock Profit Surge Leaves Durability Questions Open - simplywall.st
Morgan Stanley (ABUS) units report near-9% Arbutus Biopharma stake in 13G/A filing - Stock Titan
Arbutus Biopharma earnings matched, revenue topped estimates By Investing.com - Investing.com Nigeria
Arbutus Biopharma (NASDAQ:ABUS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Arbutus Biopharma earnings matched, revenue topped estimates - Investing.com
Arbutus Biopharma Announces Q2 2026 Financial Results Highlighting Genevant License Revenue Impact - Kalkine Media
ABUS Looks 90.7% Undervalued on GF Value™ Despite Revenue Challe - GuruFocus
What's Next for Arbutus Biopharma Corp (ABUS) After Q2 Earnings - GuruFocus
Form 8K Arbutus Biopharma Corp For: 12 August By Investing.com - Investing.com Nigeria
Arbutus Biopharma Corp 2026: Revenue $1.01M, EPS ($0.03) — 10-Q Summary - TradingView
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Arbutus: Q2 Earnings Snapshot - KTVB
Arbutus Biopharma (ABUS) swings to $164.6M H1 profit on $178.4M Moderna payout - Stock Titan
Arbutus Hepatitis B Drug Moves Toward Proposed Phase 2b Trial - Stock Titan
American Public Education and Arbutus Biopharma Post Notable Stock Returns - Markets Mojo
Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage? - Yahoo Finance
Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Arbutus Biopharma Corp (I9DN.DU) stock price, news, quote and history - Yahoo Finance Australia
Arbutus Biopharma Corp (I9DN.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Arbutus Biopharma (ABUS) Institutional Ownership 2026 - MarketBeat
Arbutus Biopharma Corp expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Arbutus Biopharma Corp (ABUS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arbutus Biopharma (ABUS) Expected to Post Earnings on Wednesday - MarketBeat
Arbutus Biopharma Corporation $ABUS Shares Acquired by Rubric Capital Management LP - MarketBeat
Arbutus Biopharma Corp (ABUS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arbutus Biopharma Corp (ABUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arbutus Biopharma Corp (ABUS) Cash Flow - TradingKey
ABUS|Arbutus Biopharma Corp|Price:4.380|Chg%:-0.090 - TradingKey
Arbutus Biopharma Corp (ABUS) Balance Sheet - TradingKey
ABUS|Arbutus Biopharma Corp|Price:4.440|Chg%:+0.060 - TradingKey
TradingKey - TradingKey
Arbutus Biopharma Corp (ABUS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arbutus Biopharma Corp (ABUS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arbutus Biopharma Corp (ABUS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arbutus Plans $230M Buyback as Patent Fight Expands - MyChesCo
US Seeks Toss Of Arbutus Patent Suit Over Moderna Vaccine - Law360
Arbutus (ABUS) Secures $178 Million Settlement with Moderna - GuruFocus
Arbutus Biopharma (ABUS) Files 8-K Announcing Agreement Termination and Key Company Details - Minichart
Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNT - GuruFocus
Arbutus (ABUS) Plans Share Buyback Program Starting Q3 - GuruFocus
Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return - Quiver Quantitative
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - The Manila Times
Arbutus awards litigation bonuses to CEO Lindsay Androski; CFO Tuan Nguyen to receive discretionary bonus - TradingView
Arbutus Biopharma (Nasdaq: ABUS) receives $178M from Moderna, eyes $230M buyback - Stock Titan
Arbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value Benchmarks - Yahoo Finance
Arbutus Biopharma stock hits 52-week high at 5.34 USD - Investing.com UK
Arbutus Biopharma stock hits 52-week high at 5.34 USD By Investing.com - Investing.com South Africa
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week - Yahoo Finance
ABUS Stock Price, Quote & Chart - ChartMill
Arbutus Biopharma Corp Stock (ABUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):